Cost-effectiveness of single-day intravenous fosaprepitant versus three-day oral aprepitant anti-emetic regimen in pediatric patients receiving highly-emetogenic chemotherapy.

被引：0

作者：

Sra, Manraj Singh ^{[1
]}

Rasheed, Azgar Abdul ^{[1
]}

Ganguly, Shuvadeep ^{[1
]}

Kumar, Santosh ^{[1
]}

Sharma, Priya ^{[1
]}

Pillai, Ashwati S. ^{[1
]}

Sharma, Swetambri ^{[1
]}

Pushpam, Deepam ^{[1
]}

Bakhshi, Sameer ^{[1
]}

机构：

[1] All India Inst Med Sci AIIMS, New Delhi, India

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

10075

引用

页数：1

共 9 条

[1] SINGLE-DAY INTRAVENOUS FOSAPREPITANT VERSUS THREE-DAY ORAL APREPITANT BASED ANTI-EMETIC REGIMEN IN PEDIATRIC PATIENTS RECEIVING HIGHLY-EMETOGENIC CHEMOTHERAPY: AN INVESTIGATOR-INITIATED, RANDOMIZED, OPEN-LABEL, NON-INFERIORITY TRIAL
Rasheed, Azgar Abdul
Ganguly, Shuvadeep
Sharma, Priya
Joison, Anu Theresa
Pillai, Ashwati S.
Sharma, Swetambri
Pushpam, Deepam
Bakhshi, Sameer
PEDIATRIC BLOOD & CANCER, 2023, 70 : S79 - S79
[2] Cost-effectiveness analysis of aprepitant-based anti-emetic regimen for children receiving highly emetogenic chemotherapy: Individual patient data analysis of a randomized trial
Sra, Manraj Singh
Ganguly, Shuvadeep
Sasi, Archana
Sharma, Priya
Giri, Rupak Kumar
Rasheed, Azgar Abdul
Bakhshi, Sameer
PEDIATRIC BLOOD & CANCER, 2022, 69 (10)
[3] Palonosetron plus a three-day aprepitant and dexamethasone schedule to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy
Mansueto, G.
Longo, F.
De Sanctis, R.
Lapadula, V.
Quadrini, S.
D'Antoni, I.
Grande, R.
Cortesi, E.
Gamucci, T.
Di Seri, M.
EJC SUPPLEMENTS, 2009, 7 (02): : 196 - 196
[4] PALONOSETRON PLUS A THREE-DAY APREPITANT AND DEXAMETHASONE SCHEDULE TO PREVENT NAUSEA AND VOMITING IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY
De Sanctis, R.
Longo, F.
Mansueto, G.
Lapadula, V
Grande, R.
Quadrini, S.
Gori, B.
Altavilla, A.
D'Antoni, I
Del Signore, E.
Stumbo, L.
Cimadon, B.
Cortesi, E.
Gamucci, T.
Di Seri, M.
ANNALS OF ONCOLOGY, 2009, 20
[5] EFFICACY AND TOLERABILITY OF A SINGLE-DAY THREE DRUG COMBINATION OF APREPITANT, PALONOSETRON AND DEXAMETHASONE IN PATIENTS RECEIVING MODERATELY EMETOGENIC CHEMOTHERAPY
Quadrini, S.
Longo, F.
Lapadula, V
Stumbo, L.
De Sanctis, R.
D'Antoni, I
Del Signore, E.
Gori, B.
Viggiani, E.
Vairano, M.
Di Seri, M.
ANNALS OF ONCOLOGY, 2009, 20
[6] Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy
Steven M. Grunberg
Matthew Dugan
Hyman Muss
Marie Wood
Susan Burdette-Radoux
Tracey Weisberg
Marisa Siebel
Supportive Care in Cancer, 2009, 17
[7] Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy
Grunberg, Steven M.
Dugan, Matthew
Muss, Hyman
Wood, Marie
Burdette-Radoux, Susan
Weisberg, Tracey
Siebel, Marisa
SUPPORTIVE CARE IN CANCER, 2009, 17 (05) : 589 - 594
[8] Single-dose NEPA versus 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with risk factors receiving moderately emetogenic chemotherapy (MEC)
Zelek, L.
Debourdeau, P.
Bourgeois, H.
Wagner, J. P.
Brocard, F.
Lefeuvre-Plesse, C.
Chauffert, B.
Leheurteur, M.
Bachet, J-B.
Simon, H.
Mayeur, D.
Jovenin, N.
Scotte, F.
ANNALS OF ONCOLOGY, 2021, 32 : S1175 - S1175
[9] PHASE III RESULTS OF A SINGLE ORAL AND A 3-DAY IV/ORAL DOSING REGIMEN FOR THE NOVEL NEUROKININ-1 (NK-1) RECEPTOR ANTAGONIST, CASPOPITANT (CAS), IN THE PREVENTION OF CINV IN PATIENTS (PTS) RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC)
Grunberg, M.
Russo, M.
Wright, O. J.
Camlett, I. I.
Herrstedt, J.
ANNALS OF ONCOLOGY, 2008, 19 : 273 - 273

← 1 →